April 11, 2014 — Calgary Scientific Inc. announced their latest Class II clearance from the U.S. Food and Drug Administration (FDA). Its enterprise image-viewing solution, ResolutionMD, is now cleared for diagnosis on mobile devices for all imaging modalities. This builds upon their previous clearances for diagnosis using web, iOS and Android devices.


April 11, 2014 — Medtronic announced CE mark and European launch of the Evera MRI SureScan implantable cardioverter-defibrillator (ICD) system, the first and only ICD system approved for magnetic resonance imaging (MRI) scans positioned on any region of the body. The Medtronic Evera MRI ICD is not approved in the United States.

April 11, 2014 — Boston Scientific Corp. has expanded the launch of its S-ICD (subcutaneous implantable cardioverter-defibrillator) system into parts of Asia. The first implant of the S-ICD in Asia was performed in Hong Kong by Hung-Fat Tse, professor of cardiovascular medicine, University of Hong Kong, and department of medicine, Queen Mary Hospital in Pokfulam, Hong Kong.

Cardiologists at Arnold Palmer Hospital for Children performed Florida’s first pediatric implant of a new device to prevent sudden cardiac arrest.

 Mitralign Inc. has completed enrollment in a study in Europe investigating its lead device, the Mitralign System, in patients with functional mitral regurgitation (FMR).

April 10, 2014 — CardioKinetix Inc. announced results of a pooled analysis study of the catheter-based Parachute ventricular partitioning device. Twelve-month clinical results from 111 consecutive U.S. and European patients with ischemic heart failure were presented at the 2014 annual meeting of the American College of Cardiology (ACC) by Philip Adamson, medical director at the Heart Failure Institute at Oklahoma Heart Hospital.


April 10, 2014 — The 2014 Guideline for the Management of Patients With Atrial Fibrillation includes recommendations for an increased use of radio frequency (RF) ablation in the treatment of non-valvular atrial fibrillation, the addition of three new anticoagulants to treatment options, a diminished role in the use of aspirin and a more comprehensive risk calculator.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now